アトピー性皮膚炎(アトピー性湿疹)治療薬の世界市場:パイプラインレビュー(2018下半期)

【英語タイトル】Atopic Dermatitis (Atopic Eczema) - Pipeline Review, H2 2018

Global Markets Directが出版した調査資料(DATA906A030)・商品コード:DATA906A030
・発行会社(調査会社):Global Markets Direct
・発行日:2018年8月28日
・ページ数:440
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥218,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥436,000見積依頼/購入/質問フォーム
Enterprisewide(複数事業所内共有可)USD6,000 ⇒換算¥654,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Atopic Dermatitis (Atopic Eczema) – Pipeline Review, H2 2018
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Atopic Dermatitis (Atopic Eczema) – Pipeline Review, H2 2018, provides an overview of the Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline landscape.

Atopic dermatitis is an itchy inflammation of skin. Signs and symptoms of atopic dermatitis include red to brownish-gray colored patches, itching, which may be severe, especially at night, small, raised bumps, which may leak fluid and crust over when scratched, thickened, cracked or scaly skin and raw, sensitive skin from scratching. Risk factors include family history of eczema, allergies, hay fever or asthma and gender.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Atopic Dermatitis (Atopic Eczema) – Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atopic Dermatitis (Atopic Eczema) (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Atopic Dermatitis (Atopic Eczema) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 10, 42, 20, 1, 46, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 4 and 2 molecules, respectively.

Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atopic Dermatitis (Atopic Eczema) (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Atopic Dermatitis (Atopic Eczema) (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atopic Dermatitis (Atopic Eczema) (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atopic Dermatitis (Atopic Eczema) (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atopic Dermatitis (Atopic Eczema) (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atopic Dermatitis (Atopic Eczema) (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atopic Dermatitis (Atopic Eczema) (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Table of Contents 2
Introduction 6
Atopic Dermatitis (Atopic Eczema) – Overview 7
Atopic Dermatitis (Atopic Eczema) – Therapeutics Development 8
Atopic Dermatitis (Atopic Eczema) – Therapeutics Assessment 26
Atopic Dermatitis (Atopic Eczema) – Companies Involved in Therapeutics Development 38
Atopic Dermatitis (Atopic Eczema) – Drug Profiles 73
Atopic Dermatitis (Atopic Eczema) – Dormant Projects 404
Atopic Dermatitis (Atopic Eczema) – Discontinued Products 412
Atopic Dermatitis (Atopic Eczema) – Product Development Milestones 414
Appendix 425

List of Tables
Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by AbbVie Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Abeome Corp, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Accolade Pharmaceuticals LLC, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Aclaris Therapeutics Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Allergan Plc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Almirall SA, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amgen Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Amorepacific Corp, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by AnaptysBio Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by AntibioTx AS, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Asana BioSciences LLC, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Bausch Health Companies Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Bioleaders Corp, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Blueberry Therapeutics Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Celgene Corp, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by ChironWells GmbH, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Clevexel Pharma SAS, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Cutanea Life Sciences Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Dermala Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by DURECT Corp, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Eli Lilly and Co, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Evelo Biosciences Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Evotec AG, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Fountain Biopharma Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Galapagos NV, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Galderma SA, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Galectin Therapeutics Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by GlaxoSmithKline Plc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Golden Biotechnology Corp, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Han Wha Pharma Co Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Heptares Therapeutics Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by iCo Therapeutics Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Immune Pharmaceuticals Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Incyte Corp, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Inflamalps SA, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Innovation Pharmaceuticals Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Japan Tobacco Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by JW Pharmaceutical Corp, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Kang Stem Biotech Co Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Kv1.3 Therapeutics, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Lead Pharma Holding BV, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by LEO Pharma A/S, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Madam Therapeutics BV, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Medicenna Therapeutics Corp, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by MedImmune LLC, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by NeoPharm Co Ltd, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by NeuroCycle Therapeutics GmbH, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Novan Inc, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Novartis AG, H2 2018
Atopic Dermatitis (Atopic Eczema) - Pipeline by Nuevolution AB, H2 2018

List of Figures
Number of Products under Development for Atopic Dermatitis (Atopic Eczema), H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

【掲載企業】

AbbVie Inc、Abeome Corp、Accolade Pharmaceuticals LLC、Aclaris Therapeutics Inc、Allergan Plc、Almirall SA、Amgen Inc、Amorepacific Corp、AnaptysBio Inc、AntibioTx AS、Asana BioSciences LLC、Aslan Pharmaceuticals Pte Ltd、Bausch Health Companies Inc、Bioleaders Corp、Blueberry Therapeutics Ltd、Celgene Corp、ChironWells GmbH、Chugai Pharmaceutical Co Ltd、Clevexel Pharma SAS、Cutanea Life Sciences Inc、Dermala Inc、DURECT Corp、Eli Lilly and Co、Evelo Biosciences Inc、Evotec AG、F. Hoffmann-La Roche Ltd、Fountain Biopharma Inc、Galapagos NV、Galderma SA、Galectin Therapeutics Inc、GlaxoSmithKline Plc、Glenmark Pharmaceuticals Ltd、Golden Biotechnology Corp、Han Wha Pharma Co Ltd、Heptares Therapeutics Ltd、iCo Therapeutics Inc、Immune Pharmaceuticals Inc、Incyte Corp、Inflamalps SA、Innovation Pharmaceuticals Inc、Japan Tobacco Inc、JW Pharmaceutical Corp、Kang Stem Biotech Co Ltd、Kv1.3 Therapeutics、Kyowa Hakko Kirin Co Ltd、Lead Pharma Holding BV、LEO Pharma A/S、Madam Therapeutics BV、Medicenna Therapeutics Corp、MedImmune LLC、NeoPharm Co Ltd、NeuroCycle Therapeutics GmbH、Novan Inc、Novartis AG、Nuevolution AB、OliX Pharmaceuticals Inc、Orbis Biosciences Inc、Otsuka Holdings Co Ltd、Pfizer Inc、Pharmedartis GmbH、Portola Pharmaceuticals Inc、Provectus Biopharmaceuticals Inc、Qurient Co Ltd、Realm Therapeutics Plc、Regeneron Pharmaceuticals Inc、Ribomic Inc、Sienna Biopharmaceuticals Inc、Signum Biosciences Inc、Spherium Biomed SL、sterna biologicals Gmbh & Co KG、TaiwanJ Pharmaceuticals Co Ltd、The Geneva Biotech Center SA、Torrent Pharmaceuticals Ltd、VivaCell Biotechnology Espana SL、vTv Therapeutics Inc、XBiotech Inc、Xencor Inc、Zhejiang I-Biological Technology Co Ltd

★調査レポート[アトピー性皮膚炎(アトピー性湿疹)治療薬の世界市場:パイプラインレビュー(2018下半期)] (コード:DATA906A030)販売に関する免責事項を必ずご確認ください。
★調査レポート[アトピー性皮膚炎(アトピー性湿疹)治療薬の世界市場:パイプラインレビュー(2018下半期)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆